U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact…

Leave a Reply

Your email address will not be published. Required fields are marked *